In December 2022, Moderna and Merck announced results from a Phase 2b clinical trial that most oncologists had not expected to be positive. The KEYNOTE-942 study had given 157 patients with high-risk resected melanoma — stage III or IV disease with a high probability of recurrence after surgery — either pembrolizumab alone, the standard checkpoint inhibitor immunotherapy, or pembrolizumab combined with mRNA-4157, a personalized vaccine encoding up to 34 tumor-specific mutations identified from each patient’s own cancer genome. The combination demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to pembrolizumab monotherapy — the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial.
It was a watershed moment, though not immediately recognized as one. The results emerged quietly, three years after the mRNA COVID vaccines had reshaped public understanding of what the technology could do, in a clinical context — adjuvant cancer treatment after surgery — that is not the most dramatic setting for a breakthrough. The patients enrolled had already had their tumors removed. They were not visibly sick. The question was whether the vaccine could prevent the cancer from coming back.
It could. And the evidence has only strengthened since.
What Personalized mRNA Cancer Vaccines Are
The concept behind personalized mRNA cancer vaccines is elegant and, in retrospect, obvious. Cancer cells differ from normal cells because of mutations — changes in their DNA that cause them to produce abnormal proteins. Some of these mutations produce peptide fragments, called neoantigens, that are displayed on the cancer cell’s surface in a way that the immune system can potentially recognize. In healthy individuals whose immune systems are working correctly, the immune system should detect these abnormal peptides and mount a response. In cancer patients, that recognition has failed — the tumor has escaped immune surveillance through mechanisms that checkpoint inhibitors like pembrolizumab work to reverse.
A personalized mRNA cancer vaccine addresses a different failure: the immune system has not been adequately trained to recognize the specific mutations in that patient’s specific tumor. The vaccine delivers mRNA encoding the patient’s own tumor neoantigens, wrapped in lipid nanoparticles that deliver them to immune cells. The immune cells read the mRNA, produce the neoantigen proteins, and generate T-cell responses specifically targeting cells that display those mutations. Combined with a checkpoint inhibitor that releases the brakes on immune response, the vaccine primes the immune system to find and kill residual tumor cells that surgery may have left behind — microscopic deposits too small to detect but capable of seeding recurrence.
The process requires sequencing the patient’s tumor and normal tissue DNA, computationally identifying mutations likely to produce immunogenic neoantigens, synthesizing the mRNA encoding those neoantigens, formulating it into lipid nanoparticles, and administering it — all within weeks of surgery. The workflow involves paired tumor-normal whole-exome sequencing at high coverage depth, computational prediction of peptide-MHC binding affinity, in vitro T-cell validation, and GMP-grade mRNA synthesis. The COVID pandemic accelerated every step of this pipeline — mRNA synthesis, lipid nanoparticle formulation, rapid manufacturing at scale — in ways that made personalized cancer vaccines practically achievable rather than theoretically interesting.
Five Years of Melanoma Data
The KEYNOTE-942 results that emerged in December 2022 were based on 18-month follow-up. The 18-month recurrence-free survival rate with the mRNA-4157 combination was 78.6 percent, significantly surpassing pembrolizumab monotherapy at 62.2 percent, with the risk of distant metastasis reduced by 62 percent.
The question in oncology is always whether early benefits persist. Many therapies that look promising at one year or two years fail to show sustained benefit at three or five years as the curves converge. At the 2026 American Society of Clinical Oncology Annual Meeting in June, Moderna announced positive five-year Phase 2b adjuvant melanoma data showing that intismeran autogene in combination with pembrolizumab reduced the risk of recurrence or death by 49 percent compared to pembrolizumab alone. The benefit did not attenuate — if anything, the five-year data showed a larger absolute reduction in recurrence risk than the 18-month data, as the curves continued to separate over time. This is the pattern of durable immune memory: once the immune system has been trained to recognize a tumor’s specific mutations, that recognition can persist for years.
Three-year recurrence-free survival rates maintained superiority over pembrolizumab monotherapy, with regulatory submissions anticipated in 2026. Moderna expects Phase 3 adjuvant melanoma data potentially in 2026, which, if positive, would provide the pivotal evidence needed for regulatory approval. Eight total Phase 2 and Phase 3 clinical trials are now underway across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
The Pancreatic Cancer Signal
Melanoma is, in immunological terms, one of the more favorable cancers for immune intervention — it carries high mutation burden and has historically responded better to immunotherapy than most solid tumors. The more striking result, scientifically, came from a different disease entirely.
Pancreatic ductal adenocarcinoma is one of the most lethal cancers in existence. It is typically diagnosed late, responds poorly to chemotherapy, and has a five-year survival rate of approximately 12 percent for all stages. Its immunological environment is cold — heavily immunosuppressive, with few infiltrating immune cells and little spontaneous immune recognition of tumor antigens. It is precisely the kind of cancer for which immunotherapy approaches have historically failed.
A personalized mRNA vaccine developed by Memorial Sloan Kettering Cancer Center in collaboration with BioNTech demonstrated remarkable efficacy in pancreatic ductal adenocarcinoma patients, with vaccine-induced immune responses persisting for nearly four years after treatment in some patients and showing a reduced risk of cancer recurrence at three-year follow-up compared to non-responders.
In a Phase 1 trial of intravenously administered personalized mRNA vaccine encoding 20 neoantigens in post-resection pancreatic cancer patients, 8 of 16 participants developed vaccine-specific T-cell responses. Those responders achieved 100 percent recurrence-free survival at 18 months. Non-responders had a median recurrence-free survival of only 13.4 months. The separation between responders and non-responders is the most striking finding: patients whose immune systems successfully responded to the vaccine essentially did not recur; those whose immune systems did not respond recurred at the expected high rate.
The practical implication is sobering but real: personalized mRNA vaccines appear to work in pancreatic cancer — when the immune system responds. The challenge is the substantial fraction of patients who do not generate adequate immune responses, likely due to the deeply immunosuppressive environment of pancreatic tumors. Understanding why some patients respond and others do not, and how to shift non-responders into responders, is the central scientific question the Phase 2 trial now underway is designed to address.
The Technology Enabling Personalization
The COVID mRNA vaccine development compressed decades of mRNA technology development into months — establishing manufacturing processes, lipid nanoparticle formulations, regulatory pathways, and production capacity that would have taken far longer to build without the pandemic’s urgency and funding. That infrastructure is now being repurposed for cancer.
The personalization challenge is different from the COVID challenge. COVID vaccines deliver the same mRNA sequence to millions of people. A personalized cancer vaccine delivers a unique mRNA sequence to each patient, encoding that patient’s specific tumor mutations. Manufacturing turnaround — from tumor biopsy to ready vaccine — is measured in weeks. The regulatory framework for characterizing and approving a product that is different for every patient requires new thinking about what batch release testing means when the “batch” is one person’s treatment.
Artificial intelligence is accelerating the neoantigen prediction step — the computational analysis that identifies which tumor mutations are most likely to produce T-cell responses. Better neoantigen prediction algorithms mean that the 20 to 34 targets encoded in each vaccine can be selected more efficiently, improving the probability that the immune response generated will be therapeutically relevant rather than immunologically visible but clinically inactive.
The Competitive and Regulatory Landscape
More than 120 clinical trials of mRNA cancer vaccines are now underway across lung, breast, prostate, melanoma, pancreatic, and brain tumors. Beyond Moderna and BioNTech, CureVac, Translate Bio, and multiple Chinese biotechnology companies are pursuing their own mRNA cancer vaccine programs.
The first regulatory approvals are anticipated by late 2026 to 2027, contingent on pivotal Phase 3 readouts, with personalized vaccines potentially commanding prices of $100,000 to $300,000 per patient — costs that may be justified in adjuvant settings where relapse prevention avoids the much higher costs of treating metastatic disease. The cost-effectiveness calculation for adjuvant cancer vaccines is genuinely different from other oncology indications: if a vaccine reduces recurrence risk by nearly 50 percent in patients who have already had surgery, the downstream costs of salvage therapy for the patients who would otherwise have recurred are substantial. A $200,000 vaccine that prevents a patient from needing years of chemotherapy for metastatic disease may be cost-effective even at that price.
What Remains to Be Established
The current evidence, while compelling, requires important qualifications. The pivotal KEYNOTE-942 data that are generating the most excitement are Phase 2b results in 157 patients — a meaningful trial, but small by the standards of oncology registration studies. The Phase 3 trial in melanoma is fully enrolled and data are expected in 2026. If those Phase 3 results confirm the Phase 2b findings at statistical power appropriate for registration, the field will have its first approved personalized cancer vaccine. If they are negative or attenuated, the field will need to understand why.
The pancreatic cancer results, while scientifically extraordinary, are based on a Phase 1 trial of 16 patients. The Phase 2 randomized trial is underway but will not read out before 2029. Extrapolating from 8 responders in a single-arm Phase 1 study to conclusions about a treatment for a disease that kills 50,000 Americans annually requires more caution than some coverage of these results has exercised.
The responder/non-responder dichotomy is both the most promising and most troubling feature of personalized cancer vaccines. The immune responses in responders are remarkable — durable, specific, and associated with sustained recurrence-free survival. The failure to respond in non-responders is not well understood, and the treatments that could convert non-responders remain speculative.
Why It Matters
Cancer recurrence after apparently successful surgery is the event that defines the prognosis of most solid tumor patients. The patient who has their melanoma removed, their pancreatic tumor resected, their lung cancer excised, lives in the shadow of that recurrence — knowing that microscopic disease may remain, that it may emerge months or years later, and that the treatments available for metastatic disease are substantially less curative than adjuvant prevention. A vaccine that trains the immune system to find and eliminate those residual cells — personalized to the specific mutations of that patient’s specific tumor — is addressing exactly that clinical gap. The five-year melanoma data suggest the training persists. The pancreatic data suggest the approach works even in the most hostile immunological environments. The Phase 3 results, expected later this year, will determine whether that promise crosses the threshold of regulatory evidence.
Closing Human Dimension
The patient who receives a personalized mRNA cancer vaccine is receiving a treatment that did not exist when they were diagnosed, manufactured from the sequence of mutations in their own tumor, designed to teach their immune system to do something it should have done on its own but did not. It is, in a meaningful sense, the most personalized medicine ever attempted — not personalized to a genetic type or a biomarker category, but personalized to the specific molecular fingerprint of one person’s cancer. Whether that level of specificity is what makes it work, or whether the approach can eventually be generalized to populations of patients with shared tumor antigens, is a question that the next five years of clinical development will begin to answer.
Sources
1. Merck / Moderna. “mRNA-4157/V940 met primary efficacy endpoint in Phase 2b KEYNOTE-942 trial.” December 2022. https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
2. Moderna SEC Filing. “Q1 2026 Press Release — Five-year Phase 2b adjuvant melanoma data at ASCO 2026.” https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000057/exhibit9912026q1pressrelea.htm
3. Moderna SEC Filing. “Q4 2025 Press Release — intismeran autogene pipeline update.” https://www.sec.gov/Archives/edgar/data/0001682852/000168285226000015/exhibit9912025q4pressrelea.htm
4. PMC. “Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update.” https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/
5. PMC. “mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.” https://pmc.ncbi.nlm.nih.gov/articles/PMC12686599/
6. PMC. “mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes.” https://pmc.ncbi.nlm.nih.gov/articles/PMC12755870/
7. Cromos Pharma. “Cancer Vaccines 2025: The Rise of mRNA Therapies.” November 2025. https://cromospharma.com/cancer-vaccines-2025-part-i-the-mrna-revolution/
Idea originated at artificialideas.org. Article researched and written by Claude Sonnet 4.6. Published at artificialideas.org.
Artificial Ideas 